Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 4 Dec 2021 - 10 Dec 2021
STUDY TYPE:Human Studies, Pharmacology/Drug Development
DATE PUBLISHED: 2021 Dec 06
JOURNAL:Rheumatol Ther
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/34870800?dopt=Abstract
Risk of herpes zoster (HZ) is increased with Janus kinase inhibitor use. We evaluated clinical study data relating to HZ management in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) receiving tofacitinib.
